Evaluation of VT-1161 for treatment of coccidioidomycosis in murine infection models

Lisa Shubitz, Hien T. Trinh, John N Galgiani, Maria L. Lewis, Annette W. Fothergill, Nathan P. Wiederhold, Bridget M. Barker, Eric R G Lewis, Adina L. Doyle, William J. Hoekstra, Robert J. Schotzinger, Edward P. Garvey

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Coccidioidomycosis, or valley fever, is a growing health concern endemic to the southwestern United States. Safer, more effective, and more easily administered drugs are needed especially for severe, chronic, or unresponsive infections. The novel fungal CYP51 inhibitor VT-1161 demonstrated in vitro antifungal activity, with MIC50 and MIC90 values of 1 and 2 μg/ml, respectively, against 52 Coccidioides clinical isolates. In the initial animal study, oral doses of 10 and 50 mg/kg VT-1161 significantly reduced fungal burdens and increased survival time in a lethal respiratory model in comparison with treatment with a placebo (P

Original languageEnglish (US)
Pages (from-to)7249-7254
Number of pages6
JournalAntimicrobial Agents and Chemotherapy
Volume59
Issue number12
DOIs
StatePublished - Dec 1 2015

Fingerprint

Coccidioidomycosis
14-alpha Demethylase Inhibitors
Southwestern United States
Coccidioides
Infection
Placebos
Health
Therapeutics
Pharmaceutical Preparations
VT-1161
In Vitro Techniques

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Evaluation of VT-1161 for treatment of coccidioidomycosis in murine infection models. / Shubitz, Lisa; Trinh, Hien T.; Galgiani, John N; Lewis, Maria L.; Fothergill, Annette W.; Wiederhold, Nathan P.; Barker, Bridget M.; Lewis, Eric R G; Doyle, Adina L.; Hoekstra, William J.; Schotzinger, Robert J.; Garvey, Edward P.

In: Antimicrobial Agents and Chemotherapy, Vol. 59, No. 12, 01.12.2015, p. 7249-7254.

Research output: Contribution to journalArticle

Shubitz, L, Trinh, HT, Galgiani, JN, Lewis, ML, Fothergill, AW, Wiederhold, NP, Barker, BM, Lewis, ERG, Doyle, AL, Hoekstra, WJ, Schotzinger, RJ & Garvey, EP 2015, 'Evaluation of VT-1161 for treatment of coccidioidomycosis in murine infection models', Antimicrobial Agents and Chemotherapy, vol. 59, no. 12, pp. 7249-7254. https://doi.org/10.1128/AAC.00593-15
Shubitz, Lisa ; Trinh, Hien T. ; Galgiani, John N ; Lewis, Maria L. ; Fothergill, Annette W. ; Wiederhold, Nathan P. ; Barker, Bridget M. ; Lewis, Eric R G ; Doyle, Adina L. ; Hoekstra, William J. ; Schotzinger, Robert J. ; Garvey, Edward P. / Evaluation of VT-1161 for treatment of coccidioidomycosis in murine infection models. In: Antimicrobial Agents and Chemotherapy. 2015 ; Vol. 59, No. 12. pp. 7249-7254.
@article{98ebc689669b4dcca727817b4f06e36f,
title = "Evaluation of VT-1161 for treatment of coccidioidomycosis in murine infection models",
abstract = "Coccidioidomycosis, or valley fever, is a growing health concern endemic to the southwestern United States. Safer, more effective, and more easily administered drugs are needed especially for severe, chronic, or unresponsive infections. The novel fungal CYP51 inhibitor VT-1161 demonstrated in vitro antifungal activity, with MIC50 and MIC90 values of 1 and 2 μg/ml, respectively, against 52 Coccidioides clinical isolates. In the initial animal study, oral doses of 10 and 50 mg/kg VT-1161 significantly reduced fungal burdens and increased survival time in a lethal respiratory model in comparison with treatment with a placebo (P",
author = "Lisa Shubitz and Trinh, {Hien T.} and Galgiani, {John N} and Lewis, {Maria L.} and Fothergill, {Annette W.} and Wiederhold, {Nathan P.} and Barker, {Bridget M.} and Lewis, {Eric R G} and Doyle, {Adina L.} and Hoekstra, {William J.} and Schotzinger, {Robert J.} and Garvey, {Edward P.}",
year = "2015",
month = "12",
day = "1",
doi = "10.1128/AAC.00593-15",
language = "English (US)",
volume = "59",
pages = "7249--7254",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "12",

}

TY - JOUR

T1 - Evaluation of VT-1161 for treatment of coccidioidomycosis in murine infection models

AU - Shubitz, Lisa

AU - Trinh, Hien T.

AU - Galgiani, John N

AU - Lewis, Maria L.

AU - Fothergill, Annette W.

AU - Wiederhold, Nathan P.

AU - Barker, Bridget M.

AU - Lewis, Eric R G

AU - Doyle, Adina L.

AU - Hoekstra, William J.

AU - Schotzinger, Robert J.

AU - Garvey, Edward P.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Coccidioidomycosis, or valley fever, is a growing health concern endemic to the southwestern United States. Safer, more effective, and more easily administered drugs are needed especially for severe, chronic, or unresponsive infections. The novel fungal CYP51 inhibitor VT-1161 demonstrated in vitro antifungal activity, with MIC50 and MIC90 values of 1 and 2 μg/ml, respectively, against 52 Coccidioides clinical isolates. In the initial animal study, oral doses of 10 and 50 mg/kg VT-1161 significantly reduced fungal burdens and increased survival time in a lethal respiratory model in comparison with treatment with a placebo (P

AB - Coccidioidomycosis, or valley fever, is a growing health concern endemic to the southwestern United States. Safer, more effective, and more easily administered drugs are needed especially for severe, chronic, or unresponsive infections. The novel fungal CYP51 inhibitor VT-1161 demonstrated in vitro antifungal activity, with MIC50 and MIC90 values of 1 and 2 μg/ml, respectively, against 52 Coccidioides clinical isolates. In the initial animal study, oral doses of 10 and 50 mg/kg VT-1161 significantly reduced fungal burdens and increased survival time in a lethal respiratory model in comparison with treatment with a placebo (P

UR - http://www.scopus.com/inward/record.url?scp=84954519328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954519328&partnerID=8YFLogxK

U2 - 10.1128/AAC.00593-15

DO - 10.1128/AAC.00593-15

M3 - Article

VL - 59

SP - 7249

EP - 7254

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 12

ER -